Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Medicine relies on the use of pharmacologically active agents (drugs) to manage and treat
disease. However, drugs are not inherently effective; the benefit of a drug is directly related …

Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …

The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic
levels, however, challenges such as rapid renal clearance, degradation or non-specific …

Context Combination therapy with insulin and glucagon-like peptide-1 receptor agonists
(GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …

Background Several pharmacological treatment options are available for type 2 diabetes;
however, many patients do not achieve optimum glycaemic control and therefore new …